Use of dasatinib in the patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia with resistance to imatinib and renal failure

Journal of Clinical Pharmacy and Therapeutics

Volumn 33, Issue 3, 2008, Pages 329-330

  Sonmez, M ^a   Cobanoglu, U ^a   Ovali, E ^a   Omay, S B ^a  

^a KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DASATINIB; IMATINIB; NILOTINIB; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; CANCER PATIENT; CANCER SURVIVAL; CASE REPORT; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; HEADACHE; HUMAN; KIDNEY FAILURE; LETTER; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MALE; NEUTROPENIA; PHILADELPHIA 1 CHROMOSOME; PLEURA EFFUSION; PROGNOSIS; RASH; THROMBOCYTOPENIA; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; KIDNEY FAILURE; MALE; PIPERAZINES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; PYRIMIDINES; REMISSION INDUCTION; THIAZOLES;

EID: 43049136215     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2008.00916.x     Document Type: Letter

References (8)

1. Talpaz M, Shah NP, Kantarjian H et al. (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. New England Journal of Medicine, 354, 2531 2541.
2. Ottmann O, Dombret H, Martinelli G et al. (2007) Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood, 110, 2309 2315.
3. Maekawa T, Ashihara E, Kimura S. (2007) The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias. International Journal of Clinical Oncology, 12, 327 340.
4. Jabbour E, Cortes JE, Giles FJ, O'Brien S, Kantarjian HM. (2007) Current and emerging treatment options in chronic myeloid leukemia. Cancer, 109, 2171 2181.
5. Tokarski JS, Newitt JA, Chang CY et al. (2006) The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Research, 66, 5790 5797.
6. Cortes J, Rousselot P, Kim DW et al. (2007) Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood, 109, 3207 3213.
7. Guilhot F, Apperley J, Kim DW et al. (2007) Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood, 109, 4143 4150.
8. Bristol Myers Squibb 2006) Sprycel (dasatinib) Prescriber Information and Personal Communication.